Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma

Video content above is prompted by the following:

• How do you approach sequencing bispecifics with other BCMA-targeted therapies, such as CAR T cells or antibody-drug conjugates?
• Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR T-cell therapies?
• Might you consider a different target
• How has the emergence of CAR T-cell therapy revolutionized your approach to sequencing different treatment classes in R/R MM?
• In what ways does the time frame of relapse—early vs late—fundamentally alter your treatment-sequencing strategies for R/R MM patients?
• What specific factors do you consider when tailoring treatment approaches for early vs late relapse?
• How do the biological and clinical characteristics of early vs late relapse influence your decision-making process?
• Discuss strategies for managing patients with high-risk cytogenetics or extramedullary disease using bispecifics.